Esperion Aiming For 50% Commercial Coverage For Nexletol

 
• By Jessica Merrill

The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.

Wooden boardwalk creates path through field of tall green grass leading to blue sky and puffy white cloud - horizontal
Esperion sees a clear path to market for Nexletol • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas